Phase I results reported at the AACR Annual Meeting 2019 in Atlanta, Georgia, USA, point to the potential of a chimeric antigen receptor T-cell therapy directed against mesothelin in patients with malignant pleural disease.

Research reported at the AACR Annual Meeting 2019 in Atlanta, Georgia, USA, shows that the incidence of prostate cancer and associated mortality has generally declined or remained steady in most of the countries with available data.

Among men initiating abiraterone acetate for advanced prostate cancer, the mortality risk may be higher for those with versus without pre-existing cardiovascular disease, suggests a real-world study presented at the AACR Annual Meeting 2019 in Atlanta, Georgia, USA.

By Shreeya Nanda medwireNews is an independent medical news service provided by Springer Healthcare. © 2019 Springer Healthcare part of the Springer Nature group AACR Annual Meeting 2019; Atlanta, Georgia, USA: 29 March–3 April See also: Lung cancer ctDNA sequencing allows timely initiation of targeted therapy Adding plasma NGS testing to routine NSCLC management could aid targeted therapy delivery

However, men with the luminal subtype appeared to derive a significantly greater benefit with apalutamide than those with the basal subtype, presenter Shibu Thomas (Janssen Research & Development, Spring House, Pennsylvania, USA) pointed out at the AACR Annual Meeting 2019 in Atlanta, Georgia, USA.

Additionally, the drug has “a manageable safety profile,” presenting author Robert Doebele (University of Colorado, Aurora, USA) told delegates at the AACR Annual Meeting 2019, held in Atlanta, Georgia, USA.

By Shreeya Nanda medwireNews is an independent medical news service provided by Springer Healthcare. © 2019 Springer Healthcare part of the Springer Nature group AACR Annual Meeting 2019; Atlanta, Georgia, USA: 29 March–3 April See also: Larotrectinib ‘potential standard of care’ for adult, pediatric TRK fusion tumors Atezolizumab, larotrectinib approvals announced by FDA

Findings from the multicohort study were reported at the AACR Annual Meeting 2019, held in Atlanta, Georgia, USA.

By Shreeya Nanda medwireNews is an independent medical news service provided by Springer Healthcare. © 2019 Springer Healthcare part of the Springer Nature group AACR Annual Meeting 2019; Atlanta, Georgia, USA: 29 March–3 April See also: KEYNOTE-028 results point to pembrolizumab efficacy in SCLC, nasopharyngeal cancer FDA approves atezolizumab for extensive-stage SCLC Veliparib shows efficacy in some patients with extensive-stage SCLC

Data from the neuroendocrine cohort of the basket DART (Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors) trial, which did not include individuals with pancreatic NETs, were presented at the AACR Annual Meeting 2019, held in Atlanta, Georgia, USA.

Christine Spencer outlines her study investigating the effect of diet and supplements on gut microbiota and response to anti-PD-1 therapy in patients with metastatic melanoma, and discusses how the findings may be relevant to other tumor types (3:43).

Researcher Vassiliki Papadimitrakopoulou describes the findings of the prospective NILE study evaluating the clinical utility of genotyping cell-free DNA in patients with a new diagnosis of metastatic non-small-cell lung cancer (3:21).

Prasad Adusumilli outlines the key results of their phase I trial showing promising safety and efficacy of a mesothelin-targeted chimeric antigen receptor T-cell therapy in patients with malignant pleural disease, and also discusses the next steps (4:09).

Roy Herbst provides his views on the phase Ib TATTON study that combined osimertinib with either the MET inhibitor savolitinib or the MEK inhibitor selumetinib in the advanced, resistant NSCLC setting (2:53).

Advisory board member and study author Lecia Sequist takes us through the findings of the savolitinib plus osimertinib cohort of the phase Ib TATTON trial of advanced non-small-cell cancer patients who have developed resistance to EGFR inhibitor therapy (4:48).